ArticleTranslational andrology and urology2025
Efficacy of microsurgical denervation of the spermatic cord in patients with chronic scrotal pain following unsuccessful varicocelectomy.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic scrotal pain (CSP) frequently persists following varicocelectomy, significantly impacting patients' quality of life and posing considerable therapeutic challenges. Recently, microsurgical denervation of the spermatic cord (MDSC) has emerged as a promising surgical alternative for managing CSP refractory to conventional varicocelectomy. This study evaluates the efficacy of MDSC as a treatment for CSP in patients who did not achieve symptomatic relief after varicocelectomy. Methods: From March 2021 to March 2023, we conducted a retrospective cohort study of 45 male patients aged ≥18 years with persistent CSP following varicocelectomy. Inclusion criteria included patients unresponsive for more than three months post-varicocelectomy to medical treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants, and anticonvulsants, and who demonstrated significant pain reduction following a spermatic cord block (SCB). Pain was assessed using the Numeric Rating Scale (NRS), a self-reported tool ranging from 0 to 10. All patients underwent MDSC based on their positive response to SCB. Results: The average follow-up period was 14.0 months. Participants experienced significant pain reduction, with mean NRS pain scores decreasing from 7.5 pre-treatment to 1.7 following the SCB, and slightly rising to 1.8 post-operation. Significant pain relief, defined as a reduction of more than 50% in NRS score, was observed in 84.4% of cases. Minimal complications were reported, including one instance of surgical site infection, one case of postoperative bleeding, and two occurrences of numbness and burning sensations. Conclusions: MDSC is a safe and effective option for the management of CSP in patients unresponsive to varicocelectomy, providing substantial pain relief with minimal complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.